Adipose Tissue-Derived Mesenchymal Stem Cells Suppress Growth of Huh7 Hepatocellular Carcinoma Cells via Interferon (IFN)-β-Mediated JAK/STAT1 Pathway <i>in vitro</i>

Byun, Chun Sung; Hwang, Soonjae; Woo, Sung Hun; Kim, Moon Young; Lee, Jin Suk; Lee, Jong In; Kong, Jee Hyun; Bae, Keum Seok; Park, Il Hwan; Kim, Sung Hoon; Eom, Young Woo

doi:10.7150/ijms.41354

Cited by 20 publications

(11 citation statements)

References 47 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NK4 modified MSCs could inhibit the growth and migration of MHCC-97H cells and tumor angiogenesis ( 64 ). In vitro , adipose tissue-derived MSCs can inhibit the growth of Huh7 HCC cells through IFN β-mediated JAK/STAT1 pathways ( 65 ). Similarly, UCMSCs could inhibit the growth of HepG2 cells and promote their apoptosis by down-regulating AFP, Bcl-2 and Survivin ( 66 ).…”

Section: Roles Of Mesenchymal Stem Cells In Liver Cancermentioning

confidence: 99%

The Roles of Mesenchymal Stem Cells in Gastrointestinal Cancers

et al. 2022

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) were reported to have strong immunomodulatory ability, and inhibit the proliferation of T cells and their immune response through cell-to-cell interactions and the generation of cytokines. With high differentiation potential and self-renewal ability, MSCs are considered to function in alleviating inflammatory responses, promoting tissue regeneration and inhibiting tissue fibrosis formation. As the most common malignancies, gastrointestinal (GI) cancers have high incidence and mortality. The accurate diagnosis, exact prognosis and treatment of GI cancers have always been a hot topic. Therefore, the potential applications of MSCs in terms of GI cancers are receiving more and more attention. Recently, there is increasing evidence that MSCs may serve as a key point in the growth, metastasis, inhibition, treatment and prognosis of GI cancers. In this review, we summarized the roles of MSCs in GI cancers, mainly focusing on esophageal cancer (EC), gastric cancer (GC), liver cancer (LC), colorectal cancer (CRC) and pancreatic cancer. Besides, we proposed MSCs as potential targets and treatment strategies for the effective treatment of GI cancers, which may provide better guidance for the clinical treatment of GI cancers.

show abstract

Section: Roles Of Mesenchymal Stem Cells In Liver Cancermentioning

confidence: 99%

The Roles of Mesenchymal Stem Cells in Gastrointestinal Cancers

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Although in vitro cellular experiments have shown that MSCs and their exosomes effectively inhibit the proliferation of hepatocellular carcinoma cell lines [ 568 – 570 ], which involves multiple signaling pathways [ 571 ], some evidence suggests that MSCs also promote the proliferation and progression of HCC [ 572 – 576 ]. The specific regulatory mechanisms regarding the promotion or suppression of tumors by MSCs remain unclear.…”

Section: Mscs For Immunocompromised Liver Diseasesmentioning

confidence: 99%

Mesenchymal stem cells-based therapy in liver diseases

Han

Jin

2022

Mol Biomed

View full text Add to dashboard Cite

Multiple immune cells and their products in the liver together form a complex and unique immune microenvironment, and preclinical models have demonstrated the importance of imbalances in the hepatic immune microenvironment in liver inflammatory diseases and immunocompromised liver diseases. Various immunotherapies have been attempted to modulate the hepatic immune microenvironment for the purpose of treating liver diseases. Mesenchymal stem cells (MSCs) have a comprehensive and plastic immunomodulatory capacity. On the one hand, they have been tried for the treatment of inflammatory liver diseases because of their excellent immunosuppressive capacity; On the other hand, MSCs have immune-enhancing properties in immunocompromised settings and can be modified into cellular carriers for targeted transport of immune enhancers by genetic modification, physical and chemical loading, and thus they are also used in the treatment of immunocompromised liver diseases such as chronic viral infections and hepatocellular carcinoma. In this review, we discuss the immunological basis and recent strategies of MSCs for the treatment of the aforementioned liver diseases. Specifically, we update the immune microenvironment of the liver and summarize the distinct mechanisms of immune microenvironment imbalance in inflammatory diseases and immunocompromised liver diseases, and how MSCs can fully exploit their immunotherapeutic role in liver diseases with both immune imbalance patterns.

show abstract

“…On the other hand, IV administration requires higher doses of MSCs to distribute over a wider area in a faster manner ( Kabat et al, 2020 ; Rady et al, 2020 ). Additionally, the timing of implantation (e.g., acute vs. delayed metastasis) is critical to enhance clinical efficacy ( Byun et al, 2020 ). When angiogenic genes are engineered into MSCs, especially if they have EPC phenotype, their transplantation serves as a viable treatment for attenuating brain inflammation and repairing the BBB ( Antonucci et al, 2011 ; Miloradovic et al, 2020 ; Pawitan et al, 2020 ; Castelli et al, 2021 ; Li et al, 2021 ).…”

Section: Stem Cell Rescue Of the Pathologic Blood-brain Barriermentioning

confidence: 99%

Treating Metastatic Brain Cancers With Stem Cells

Sadanandan

Shear

Brooks

et al. 2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Stem cell therapy may present an effective treatment for metastatic brain cancer and glioblastoma. Here we posit the critical role of a leaky blood-brain barrier (BBB) as a key element for the development of brain metastases, specifically melanoma. By reviewing the immunological and inflammatory responses associated with BBB damage secondary to tumoral activity, we identify the involvement of this pathological process in the growth and formation of metastatic brain cancers. Likewise, we evaluate the hypothesis of regenerating impaired endothelial cells of the BBB and alleviating the damaged neurovascular unit to attenuate brain metastasis, using the endothelial progenitor cell (EPC) phenotype of bone marrow-derived mesenchymal stem cells. Specifically, there is a need to evaluate the efficacy for stem cell therapy to repair disruptions in the BBB and reduce inflammation in the brain, thereby causing attenuation of metastatic brain cancers. To establish the viability of stem cell therapy for the prevention and treatment of metastatic brain tumors, it is crucial to demonstrate BBB repair through augmentation of vasculogenesis and angiogenesis. BBB disruption is strongly linked to metastatic melanoma, worsens neuroinflammation during metastasis, and negatively influences the prognosis of metastatic brain cancer. Using stem cell therapy to interrupt inflammation secondary to this leaky BBB represents a paradigm-shifting approach for brain cancer treatment. In this review article, we critically assess the advantages and disadvantages of using stem cell therapy for brain metastases and glioblastoma.

show abstract

Adipose Tissue-Derived Mesenchymal Stem Cells Suppress Growth of Huh7 Hepatocellular Carcinoma Cells via Interferon (IFN)-β-Mediated JAK/STAT1 Pathway in vitro

Cited by 20 publications

References 47 publications

The Roles of Mesenchymal Stem Cells in Gastrointestinal Cancers

The Roles of Mesenchymal Stem Cells in Gastrointestinal Cancers

Mesenchymal stem cells-based therapy in liver diseases

Treating Metastatic Brain Cancers With Stem Cells

Contact Info

Product

Resources

About